Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

Inclusion Criteria: * Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-S3 based on the presence of an actionable mutation as defined in EAY191 * GENERAL COMBOMATCH EAY191 REGISTRATION INCLUSION CRITERIA: * Participants must be enrolled on the ComboMATCH Master Registration Trial EAY191 * Participants must have an activating AKT mutation (a known mutation in AKT1, AKT2, or AKT3, a single nucleotide variant, insertion, or deletion), PTEN mutation (a known mutation in PTEN, a single nucleotide variant, insertion, or deletion), or genomic deletion loss of PTEN as determined by the ComboMATCH screening assessment * GENERAL COMBOMATCH EAY191 REGISTRATION EXCLUSION CRITERIA: * Participants must not have an activating KRAS, NRAS, HRAS, or BRAF mutation (a single nucleotide variant, insertion, or deletion) as determined by the ComboMATCH screening assessment * Participants must have disease that can be safely biopsied and agree to a pre-treatment biopsy or have archival tissue available from within 12 months prior to the date of registration on the ComboMATCH Registration Trial (EAY191) * Participants must have a histologically confirmed non-breast solid malignancy * Participants must have locally advanced, unresectable, or metastatic disease in the opinion of the treating investigator * Participants must have measurable disease documented by CT or MRI. Measurable disease must be assessed within 28 days prior to registrati…